Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on September 28, 2006

Arteriosclerosis, Thrombosis, and Vascular Biology. 2006
Published online before print September 28, 2006, doi: 10.1161/01.ATV.0000248101.93488.84
A more recent version of this article appeared on December 1, 2006
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
26/12/2731    most recent
01.ATV.0000248101.93488.84v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lalloyerc, F.
Right arrow Articles by Tailleux, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lalloyerc, F.
Right arrow Articles by Tailleux, A.

Submitted on March 23, 2006
Accepted on September 14, 2006

The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia

Fanny Lalloyerc ; Catherine Fiévet ; Sophie Lestavel ; Gérard Torpier ; Jelske van der Veen ; Véronique Touche ; Stéphanie Bultel ; Saïd Yous ; Folkert Kuipers ; Réjane Paumelle ; Jean-Charles Fruchart ; Bart Staels ; and Anne Tailleux *

From Institut Pasteur de Lille (F.L., C.F., S.L., G.T., V.T., S.B., R.P., J.-C.F., B.S., A.T.), Département d’Athérosclérose, Lille, France; Inserm (F.L., C.F., S.L., G.T., V.T., S.B., R.P., J.-C.F., B.S., A.T.), U545, Lille, France; Université de Lille 2 (F.L., C.F., S.L., G.T., V.T., S.B., R.P., J.-C.F., B.S., A.T.), Lille, France; Center for Liver, Digestive, and Metabolic Disease (J.v.d.V., F.K.), University Medical Center Groningen, Groningen, The Netherlands; Institut de Chimie Pharmaceutique Albert Lespagnol (S.Y.), Université de Lille 2, Lille, France.

* To whom correspondence should be addressed. E-mail: Anne.Tailleux{at}pasteur-lille.fr.

Objective--The activity of the antitumoral agent bexarotene (Targretin, Bexarotene) depends on its binding to the nuclear retinoid-X receptor (RXR) and subsequent transcriptional regulation of target genes. Through RXR activation, bexarotene may modulate numerous metabolic pathways involved in atherosclerosis. Here, we investigated the effect of bexarotene on atherosclerosis progression in a dyslipidemic murine model, the human apolipoprotein E2 knockin mouse, that develops essentially macrophage-laden lesions.

Methods and Results--Atherosclerotic lesions together with different metabolic pathways involved in atherosclerosis were investigated in mice treated or not with bexarotene. Bexarotene protects from atherosclerosis development in mice, at least in part by improving the circulating cholesterol distribution profile likely via a marked decrease of dietary cholesterol absorption caused by modulation of intestinal expression of genes recently identified as major players in this process, Niemann-Pick-C1-Like1 (NPC1L1) and CD13. This atheroprotection appears despite a strong hypertriglyceridemia. Moreover, bexarotene treatment only modestly modulates inflammatory gene expression in the vascular wall, but markedly enhanced the capacity of macrophages to efflux cellular lipids.

Conclusion--These data provide evidence of a favorable pharmacological effect of bexarotene on atherosclerosis despite the induction of hypertriglyceridemia, likely via a beneficial action on intestinal absorption and macrophage efflux.
Key words: atherosclerosis • cholesterol homeostasis • intestinal cholesterol absorption • rexinoid • triglycerides




This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. Lalloyer, T. A. Pedersen, B. Gross, S. Lestavel, S. Yous, E. Vallez, J.-A. Gustafsson, S. Mandrup, C. Fievet, B. Staels, et al.
Rexinoid Bexarotene Modulates Triglyceride but not Cholesterol Metabolism via Gene-Specific Permissivity of the RXR/LXR Heterodimer in the Liver
Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1488 - 1495.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. de Vries-van der Weij, W. de Haan, L. Hu, M. Kuif, H. L. D. W. Oei, J. W. A. van der Hoorn, L. M. Havekes, H. M. G. Princen, J. A. Romijn, J. W. A. Smit, et al.
Bexarotene Induces Dyslipidemia by Increased Very Low-Density Lipoprotein Production and Cholesteryl Ester Transfer Protein-Mediated Reduction of High-Density Lipoprotein
Endocrinology, May 1, 2009; 150(5): 2368 - 2375.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
A. Harari, D. Harats, D. Marko, H. Cohen, I. Barshack, Y. Kamari, A. Gonen, Y. Gerber, A. Ben-Amotz, and A. Shaish
A 9-cis {beta}-Carotene-Enriched Diet Inhibits Atherogenesis and Fatty Liver Formation in LDL Receptor Knockout Mice
J. Nutr., October 1, 2008; 138(10): 1923 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
T. L. Horn, K. E. O. Torres, J. M. Naylor, M. J. Cwik, C. J. Detrisac, I. M. Kapetanovic, R. A. Lubet, J. A. Crowell, and D. L. McCormick
Subchronic Toxicity and Toxicogenomic Evaluation of Tamoxifen Citrate + Bexarotene in Female Rats
Toxicol. Sci., October 1, 2007; 99(2): 612 - 627.
[Abstract] [Full Text] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.